SENSORION SA
GGETTEX:A41Z9F10.28
EUR
- -
- -
SENSORION SA
GETTEX:A41Z9F
(Gettex)
Recent
price
10.28
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Sensorion SA is a France-based clinical-stage biotechnology company dedicated to the development of novel therapeutics and gene therapies for the prevention and treatment of inner ear disorders, hearing loss, and vestibular dysfunctions. Founded in 2009 and headquartered in Montpellier, France, the company leverages specialized otology research platforms to address severe unmet medical needs in hereditary deafness, acoustic trauma, ototoxicity, and balance disorders. The company's core product development pipeline comprises small molecule therapeutics and dual adeno-associated virus (AAV) vector gene therapies: SENS-401 (araziditid), an orally available neuroprotective small molecule calpain inhibitor developed for the preservation of residual hearing following cochlear implantation, the prevention of cisplatin-induced ototoxicity in oncology patients, and the treatment of acute unilateral vestibulopathy; SENS-501 (OTOF-GT), a dual AAV vector gene therapy designed to restore hearing in pediatric patients suffering from otoferlin gene (DFNB9) mutations causing profound congenital sensorineural deafness; GJB2-GT, a gene therapy program targeted at mutations in the GJB2 gene encoding connexin 26, addressing both early-onset childhood non-syndromic hearing impairment and progressive adult hearing loss; and USH1G-GT, a pre-clinical gene therapy program targeting Usher Syndrome Type 1G to treat congenital sensorineural hearing loss and vestibular deficit. Sensorion conducts operations primarily from its facilities in France while coordinating international clinical trials and research partnerships throughout Europe and North America. In recent developments, the company has progressed its clinical gene therapy franchise by initiating the Phase 1/2 Audiogene clinical trial for SENS-501 following clinical trial authorizations across multiple European jurisdictions, including France, the United Kingdom, and Spain. Additionally, Sensorion completed significant private placement financing rounds backed by prominent international healthcare investors such as Sofinnova Partners, Invus, Redmile Group, and Perceptive Advisors to advance its clinical pipeline. The company continues its strategic research collaboration with the Institut Pasteur for the development of gene therapy programs targeting monogenic forms of hearing loss, as well as its strategic clinical collaboration with Cochlear Limited evaluating the combination of SENS-401 with cochlear implant procedures.